Answers are grounded in this paper and cite their sources.
Analysis reveals elevated MMP-1 levels as a poor prognostic factor in ovarian cancer, suggesting improved prediction when combined with CA125.
This study aimed to investigate whether matrix metalloproteinase-1 (MMP-1) expression serves as a poor prognostic factor in patients with ovarian cancer. A total of 74 patients who underwent surgery for ovarian cancer at Tottori University Hospital between 2017 and 2022 were retrospectively analyzed. Preoperative serum MMP-1 levels were measured using a sandwich ELISA, and tumor tissue expression of MMP-1 was evaluated using immunohistochemistry. Associations between MMP-1 levels and clinical outcomes, including overall survival (OS) and progression-free survival (PFS), were assessed using Kaplan-Meier and Cox regression analyses. Elevated serum MMP-1 concentration was identified as an independent poor prognostic factor for overall survival (OS). However, MMP-1 expression in tumor tissue was not an independent prognostic factor for either OS or progression-free survival (PFS). Preoperative serum MMP-1 levels showed a positive correlation with Cancer Antigen 125 (CA125), indicating that the combination of these markers may be useful for predicting prognosis. Serum MMP-1 concentration may serve as a poor prognostic biomarker in ovarian cancer. Its use alongside CA125 could enhance prognostic assessment.
No takes yet. Share an insight, caveat, or question.
Hikino et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: